# PrimeraDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/primeradx

- Industry: Biotechnology
- Headquarters: Mansfield, US
- Website: www.primeradx.com
- Total disclosed funding: $54M
- Latest round: Series C (Sep 8, 2009)
- Investors on record: 7

## About

PrimeraDx Inc. focuses on advancing molecular diagnostics through its innovative quantitative multiplex PCR technology, delivering precise genetic testing solutions to enhance healthcare outcomes.PrimeraDx Inc. specializes in molecular diagnostics, providing tools for genetic testing. Founded in 2004 and headquartered in Mansfield, Massachusetts, US, the company has successfully completed 8 deals. In June 2014, it raised USD 19.76 mn through a SERIES C funding round led by CHL Medical Partners, contributing to a total amount raised of USD 19.76 mn, resulting in a current company valuation of USD 39.335 mn.PrimeraDx specializes in molecular diagnostics, particularly through its innovative quantitative multiplex PCR technology. The company's core product offerings focus on providing comprehensive solutions for genetic testing, enabling healthcare professionals to diagnose various diseases with high precision and speed. These products are designed to address critical needs in areas such as oncology, infectious diseases, and inherited genetic disorders. The end users primarily include hospitals, clinical laboratories, and research institutions that seek reliable testing methods to enhance patient outcomes. Currently, PrimeraDx's products are marketed in North America and Europe, where they have established a robust client base comprising healthcare providers committed to advancing diagnostic capabilities.PrimeraDx generates revenue through a structured business model that encompasses direct sales to healthcare providers and partnerships with clinical laboratories. Transactions typically involve the sale of diagnostic testing kits, which are purchased in bulk by hospitals and labs, facilitating their ability to offer advanced genetic testing services to patients. The company offers various pricing plans that reflect the complexity and specificity of its flagship products, including proprietary multiplex PCR assays. These plans are tailored to meet the needs of different customers, ensuring that healthcare facilities can access essential diagnostic tools while maintaining cost efficiency. The recurring revenue potential is evident through ongoing contracts and support agreements with key clients, enhancing the company's financial stability and market presence.In June 2014, Qiagen acquired PrimeraDx Inc. The financial terms of the deal were not disclosed. This acquisition indicates a strategic move towards expanding PrimeraDx's reach in the molecular diagnostics market.

## Funding rounds

- Series C, Sep 8, 2009, $20M — Abingworth, Burrill & Company, CHL Medical Partners, InterWest Partners, Malaysian Technology Development, Invus [DUP], MPM BioImpact
- Series B, Jan 8, 2008, $21M — Abingworth, Burrill & Company, InterWest Partners, Malaysian Technology Development, Invus [DUP], MPM BioImpact
- Series A, Nov 21, 2007, $2.5M — Burrill & Company, Malaysian Technology Development, MPM BioImpact
- Series A, Jul 11, 2005, $11M — Burrill & Company, Malaysian Technology Development, MPM BioImpact

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A, Series B, Series C
- Malaysian Technology Development (https://capitalatlas.ai/funds/malaysian-technology-development) — Series A, Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series B, Series C
- Invus [DUP] — Series B, Series C
- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series C